WEST PHARMACEUTICAL SERVICES INC (WST)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

2Y 5Y 10Y All
Quarterly Annual TTM

Revenue Annual

0 1.5B 3B 4.5B FY08: 1.1B FY09: 1.1B FY10: 1.1B FY11: 1.2B FY12: 1.3B FY13: 1.4B FY14: 1.4B FY15: 1.4B FY16: 1.5B FY17: 1.6B FY18: 1.7B FY19: 1.8B FY20: 2.1B FY21: 2.8B FY22: 2.9B FY23: 2.9B FY24: 2.9B FY25: 3.1B FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Gross Profit Annual

0 400M 800M 1.2B FY08: 302.6M FY09: 303.6M FY10: 318.1M FY11: 339.3M FY12: 387.7M FY13: 434.7M FY14: 447.8M FY15: 455.8M FY16: 501.4M FY17: 512.9M FY18: 545.4M FY19: 605.7M FY20: 767.8M FY21: 1.2B FY22: 1.1B FY23: 1.1B FY24: 998.5M FY25: 1.1B FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Operating Income Annual

0 300M 600M 900M FY08: 124.1M FY09: 97.5M FY10: 90.7M FY11: 109.6M FY12: 135.1M FY13: 162.4M FY14: 182M FY15: 128.6M FY16: 195.2M FY17: 225.8M FY18: 240.3M FY19: 296.6M FY20: 406.9M FY21: 752.3M FY22: 734M FY23: 676M FY24: 569.9M FY25: 584.9M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Net Income Annual

0 250M 500M 750M FY08: 86M FY09: 72.6M FY10: 65.3M FY11: 75.5M FY12: 80.7M FY13: 112.3M FY14: 127.1M FY15: 95.6M FY16: 143.6M FY17: 150.7M FY18: 206.9M FY19: 241.7M FY20: 346.2M FY21: 661.8M FY22: 585.9M FY23: 593.4M FY24: 492.7M FY25: 493.7M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Cost of Revenue Annual

0 700M 1.4B 2.1B FY08: 748.5M FY09: 752.1M FY10: 786.6M FY11: 853M FY12: 878.7M FY13: 933.7M FY14: 973.6M FY15: 944M FY16: 1B FY17: 1.1B FY18: 1.2B FY19: 1.2B FY20: 1.4B FY21: 1.7B FY22: 1.8B FY23: 1.8B FY24: 1.9B FY25: 2B FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Operating Cash Flow Annual

0 300M 600M 900M FY08: 135M FY09: 137.7M FY10: 138.3M FY11: 130.7M FY12: 187.4M FY13: 220.5M FY14: 182.9M FY15: 212.4M FY16: 219.4M FY17: 263.3M FY18: 288.6M FY19: 367.2M FY20: 472.5M FY21: 584M FY22: 724M FY23: 776.5M FY24: 653.4M FY25: 754.8M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Free Cash Flow Annual

-200M 0 200M 400M 600M FY08: -3.6M FY09: 32.8M FY10: 67.2M FY11: 35.3M FY12: 56.1M FY13: 68.6M FY14: 71M FY15: 80.8M FY16: 49.2M FY17: 132.5M FY18: 183.9M FY19: 240.8M FY20: 298.1M FY21: 330.6M FY22: 439.4M FY23: 414.5M FY24: 276.4M FY25: 468.9M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 30M 60M 90M FY08: 36.1M FY09: 36.3M FY10: 36.7M FY11: 74M FY12: 71.8M FY13: 71.4M FY14: 72.8M FY15: 73.8M FY16: 75M FY17: 75.8M FY18: 75.4M FY19: 75.4M FY20: 75.8M FY21: 76.3M FY22: 75.8M FY23: 75.3M FY24: 73.7M FY25: 72.7M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

0.00 3.50 7.00 10.50 Q4 '09: 2.12 Q1 '10: 2.23 Q2 '10: 2.28 Q3 '10: 2.29 Q4 '10: 1.89 Q1 '11: 1.88 Q2 '11: 1.83 Q3 '11: 1.81 Q4 '13: 1.57 Q1 '14: 1.50 Q2 '14: 1.59 Q3 '14: 1.65 Q4 '14: 1.76 Q1 '15: 1.83 Q2 '15: 1.69 Q3 '15: 1.28 Q4 '15: 1.30 Q1 '16: 1.15 Q2 '16: 1.37 Q3 '16: 1.85 Q4 '16: 1.91 Q1 '17: 2.42 Q2 '17: 2.33 Q3 '17: 2.50 Q4 '17: 1.99 Q1 '18: 1.76 Q2 '18: 2.00 Q3 '18: 2.06 Q4 '18: 2.75 Q1 '19: 2.90 Q2 '19: 3.03 Q3 '19: 3.05 Q4 '19: 3.20 Q1 '20: 3.46 Q2 '20: 3.79 Q3 '20: 4.13 Q4 '20: 4.58 Q1 '21: 5.58 Q2 '21: 6.84 Q3 '21: 8.06 Q4 '21: 8.66 Q1 '22: 8.96 Q2 '22: 8.97 Q3 '22: 8.25 Q4 '22: 7.73 Q1 '23: 7.29 Q2 '23: 6.87 Q3 '23: 7.42 Q4 '23: 7.88 Q1 '24: 7.58 Q2 '24: 7.03 Q3 '24: 6.74 Q4 '24: 6.69 Q1 '25: 6.37 Q2 '25: 6.68 Q3 '25: 6.75 Q4 '25: 6.79 Q1 '26: 7.48 Q2 '26: 7.81 Q2 '10 Q2 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.